The 4 States With the Most Psychopaths Might Surprise You
According to a massive new study led by researchers at the University of Copenhagen, certain places in the U.S. are more likely to produce people with what psychologists call "dark" personality traits. Four states top the list.
The study analyzed data from more than 2 million people across 183 countries and all 50 U.S. states. Researchers looked at dark traits like psychopathy, narcissism, and Machiavellianism, and compared them with what they called "adverse societal conditions" — things like poverty, inequality, corruption, and violence.
The findings were clear: people living in harsher environments tend to score higher on the so-called "Dark Factor."
So which U.S. states stood out? Nevada, New York, South Dakota, and Texas topped the rankings for the highest levels of these traits.
The researchers relied on crime rates, poverty stats, and corruption convictions to draw their conclusions. The results were consistent. People living in places with more societal dysfunction are more likely to show signs of selfishness, aggression, and a willingness to exploit others.
Lead researcher Ingo Zettler explained that the study doesn't mean people in those states are doomed to be bad actors. However, it does suggest that our surroundings shape us more than we might think.
"Even small variations can lead to large differences in how societies function," he said.
On the flip side, the states with the lowest levels of dark traits were Vermont, Utah, Maine, and Oregon. These areas tend to be more economically balanced and socially stable, creating environments that, according to the study, are less likely to foster toxic behavior.
The takeaway? Dark personality traits aren't just something we're born with. They're also a product of the world we live in.
While the data can't predict individual behavior, it paints a sobering picture of how deep the connection between society and psychology really runs.The 4 States With the Most Psychopaths Might Surprise You first appeared on Men's Journal on Jun 18, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
US pediatric group breaks with CDC advice, recommends COVID vaccines for young children
The American Academy of Pediatrics released its vaccine recommendations on Aug. 19 in a break from federal guidance shaped by Health and Human Services Secretary Robert F. Kennedy Jr. The AAP, in tandem with multiple other professional medical associations, previously decried a May announcement made by Kennedy Jr. that the COVID-19 vaccine would no longer be included in the Centers for Disease Control's recommended immunizations for healthy children and pregnant women, a move that went against previous expert guidance and bypassed the normal scientific review process. The AAP, a professional organization of over 65,000 board-certified pediatricians dedicated to advancing children's medicine, said in a June 26 statement that it would "continue to publish its own evidence-based recommendations and schedules," as the creation of federal immunization policy is 'no longer a credible process." Kennedy Jr. drew further ire from medical communities when he fired all 17 original members of the Advisory Committee on Immunization Practices, the committee of health experts that provides guidance on vaccine use to the CDC, replacing them with members that critics have called unqualified. Some of the members, like Kennedy Jr., have a history of anti-vaccine advocacy and involvement in anti-vaccine groups. Here's what to know about the new AAP guidance and how it differs from federal guidelines. What is the AAP guidance on COVID-19 vaccines for children? The AAP schedule lists which vaccines children should get at certain ages and provides updated guidance on influenza, RSV, and COVID-19 immunizations for children and adolescents from birth to age 18. The schedule recommends that all children between six months and 23 months receive the latest COVID-19 vaccine to reduce the chance of serious illness. Children and adolescents aged 2 to 18, without other high-risk factors like immunosuppression, can receive and should be offered the vaccine if they were not previously immunized, according to the guidance. Children, teens, and adults alike who are at increased risk of serious infection should receive the vaccine if they have not already, AAP said, adding that its recommendation differed from the CDC, which it said is now staffed with people who have a history of spreading vaccine misinformation. "The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children, and adolescents," AAP President Dr. Susan J. Kressly, MD, said in a statement. "Pediatricians know how important routine childhood immunizations are in keeping children, families and their communities healthy and thriving." What is the federal guidance on COVID-19 vaccines for children? The CDC did not go as far as completely removing COVID-19 vaccination from its immunization schedule despite Kennedy Jr.'s insistence. Instead, the agency changed its language from recommending the vaccine annually to suggesting parents consult with their child's physician on whether to vaccinate. Kennedy Jr. previously said that the CDC planned only to recommend the COVID vaccine for people over the age of 65 and those at high personal risk of infection, though the agency's website still contains information recommending it for everyone over the age of six months. A notice on the top webpages on the topic reads, "COVID-19 vaccine recommendations have recently been updated for some populations. This page will be updated to align with the updated immunization schedule," as of Aug. 19. This change to whom the vaccine is recommended could make it harder for others who want the COVID-19 vaccine to get it, experts warned. Since insurance coverage typically follows federal recommendations, anyone who wants the shot but isn't on the CDC's recommendation list may have to pay the price out of pocket HHS Communications Director Andrew Nixon defended the decision in a statement to USA TODAY, accusing the AAP, which receives funding from pharmaceutical companies like Pfizer, of failing to have proper conflict-of-interest safeguards in place. "By bypassing the CDC's advisory process and freelancing its own recommendations, while smearing those who demand accountability, the AAP is putting commercial interests ahead of public health and politics above America's children," Nixon said. Kennedy Jr. shared a separate response on social media on Aug. 19, pointing out that the agency's top donors are four companies that "make virtually every vaccine on the CDC recommended childhood vaccine schedule" and saying that the AAP recommendations are "corporate-friendly" and may "promote commercial ambitions of AAP's Big Pharma benefactors" instead of public health. "AAP should also be candid with doctors and hospitals that recommendations that diverge from the CDC's official list are not shielded from liability under the 1986 Vaccine Injury Act," his post concluded. USA TODAY reached out to AAP for comment on Aug. 19 but has not received a response. The new Advisory Committee on Immunization Practices didn't vote on COVID-19 vaccine recommendations when they met in June and are expected to reconvene in "September/October," according to the CDC. The FDA has signaled intentions to revoke the Pfizer COVID-19 shot for young, healthy children. In early August, HHS announced that it would pull $500M in funding from mRNA vaccine research and development. This article originally appeared on USA TODAY: Young kids should receive COVID vaccine despite CDC advice: AAP Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 19, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using XtalPi's proprietary AI-driven drug discovery platform. The XtalPi platform combines the speed and generative power of AI with the accuracy of its robotic lab-in-the-loop to accelerate drug discovery and vastly expand the explorable chemical space. This integrated workflow spans deep-learning-based molecule design, quantum physics and molecular dynamics simulations for predicting drug-target interactions, automated chemical synthesis, and experimental validation of candidate compounds' key pharmaceutical properties. Leveraging its expertise in immunology and inflammation as well as its experience in small molecule drug development, Dong-A ST will actively participate throughout the entire R&D process—including candidate validation, efficacy and safety testing, and the formulation of preclinical and clinical development strategies. The company also plans to explore strategies for pipeline expansion and assess commercialization potential. Through this partnership, Dong-A ST aims to strengthen its pipeline in the immunology and inflammation space and expand its R&D scope beyond small molecule therapeutics into areas such as targeted protein degradation (TPD), biologics, antibody-drug conjugates (ADC), and gene therapies. John Wang, Senior Vice President of Drug Discovery at XtalPi, stated: "The combination of Dong-A ST's extensive expertise and XtalPi's proven AI-robotics platform is well-positioned to translate scientific innovation into competitive precision medicines. Together, we aim to rapidly discover and rigorously validate novel drug candidates across multiple modalities to unlock unique market opportunities, and deliver transformative therapies for global patients." Jae-Hong Park, Head of R&D at Dong-A ST, remarked, "This collaboration marks a pivotal step in expanding Dong-A ST's R&D capabilities," adding, "By leveraging synergies with XtalPi's AI platform, we expect to accelerate the development of next-generation treatments for immune and inflammatory diseases." Meanwhile, both Dong-A ST and XtalPi operate open innovation offices in Boston, USA. This geographic proximity will facilitate closer and more efficient collaboration throughout the drug discovery process. About Dong-A ST Dong-A ST Co., Ltd. ( was established in 1932 and is a leading Korean pharmaceutical company engaged in the development, manufacturing, and commercialization of ethical drugs, biosimilars, medical devices, and diagnostics. Its key products include Stillen (gastritis), Zydena (erectile dysfunction), Motilitone (functional dyspepsia), and Imuldosa (ustekinuma biosimilar). Leveraging strong R&D capabilities and a history of innovation, Dong-A ST is expanding its pipeline in immunology, inflammation, neurological disease, metabolic diseases, and oncology, while advancing into new modalities such as biologics, ADCs, TPD, and gene therapies. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Sign in to access your portfolio
CNN
an hour ago
- CNN
FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination
Federal agencies Food & healthFacebookTweetLink Follow The US Food and Drug Administration on Tuesday urged the public not to eat certain bags of frozen raw shrimp sold at Walmart, citing concerns about unsanitary conditions and radioactive contamination found in shipments from the same supplier. The FDA said that a radioactive isotope, cesium-137, was detected in a sample of breaded shrimp detained at US ports – in Los Angeles, Houston, Savannah, and Miami – from an Indonesian supplier named BMS Foods. Those contaminated shipments never reached the US market. However, because Walmart's raw frozen shrimp came from the same supplier – and the agency said it 'appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137' – officials advised consumers to avoid eating them. The levels of cesium detected – about 68 becquerels per kilogram – were well below the FDA's intervention level of 1,200 Bq/kg. Still, regulators issued the advisory out of caution, citing the potential risks of cancer from long-term, low-dose exposure and problems at the supplier's facility. The advisory applies to 2-pound Great Value bags of white vannamei shrimp, all carrying a best-by date of March 15, 2027. They were distributed to Walmart stores in at least 13 states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. The agency is advising consumers who purchased the shrimp to throw it away or return it, and, said an investigation is ongoing in conjunction with Indonesian seafood regulatory authorities. Walmart confirmed to CNN that it 'immediately recalled the product from impacted stores.' CNN has also reached out to the supplier for comment.
